 
|
|
TB/HIV Working Group |
|
Home | TB/HIV Working Group | Meetings and Events | Key Issues in implementation | Publications | Contact Us
|
|
|
|
Meetings and Events
Core Group Meetings Meetings 2008 Archive  The Shack interior, AIDS 2008 Conference, Mexico |
Summary of the TB/HIV Research Frontiers meetingCROI 2010, San Francisco, USAThe Stop TB Department of the World Health Organization and the Consortium to Respond Effectively to the AIDS/TB Epidemic organized an HIV/TB research frontiers meeting on behalf of the TB/HIV Working Group of the Stop TB Partnership affiliated with the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) in San Francisco, USA on February 16, 2010 . This is the fourth in a series of meetings organized by WHO and CREATE since 2007. The meeting was co-chaired by Dr Kenneth Castro , Assistant Surgeon General and Director of Division of Tuberculosis Elimination Centers for Disease Control and Prevention and Dr Alison Grant , Head of the Clinical Research Unit in London School of Hygiene and Tropical Medicine. The meeting was opened by Dr Diane Havlir, the chair of the TB/HIV Working Group who described the popularity of the meetings among HIV researchers to stimulate scientific debates and discussions around HIV/TB. The meeting was attended by more than 65 HIV researchers and public health policy makers. The main objective of the meeting was to promote high level scientific interchange of ideas and debates around isoniazid preventive therapy (IPT) and its role in improving survival among people living with HIV so as to generate questions for future research. New data on the impact of IPT on mortality of people living with HIV was presented from Botswana, India and South Africa. Dr Craig Innes (Innes_San Francisco CROI 2010) , from Aurum Institute of South Africa presented the result of a retrospective observational study of more than 3200 patients on ART, which shows the combined use of IPT and ART may reduce the risk of death by nearly 50%. Dr Soumya Swaminathan (Swaminathan_San Francisco CROI 2010) from the TB Research Center in Chennai, India presented a randomized controlled trial with a sample size of 752 that compares 6 month INH and Ethambutol versus 36 month INH which showed no statistically significant difference in mortality in both arms. She said most of the mortality occurred during the first 12 months and there was no difference in mortality based on tuberculin skin test (TST) status. Dr Taraz Samandari from CDC presented a preliminary report of mortality from the Botswana IPT randomized controlled trial with a sample size of 2000 that compares 6 month IPT versus 36 months. He reported that there was non-significant increase in mortality in the 36 months arm than the 6 months. They observed three fold increased death in TST negatives as compared to TST positives, in contrast to the Indian trial. However, further clinical characterization of the two deaths that were attributed to hepatic encephalopathy (observed among TST negatives) was not conclusive. Dr Richard Chaisson of John Hopkins and CREATE provided commentary on the role of IPT and mortality and underscored the primary objective of IPT is to prevent TB rather than improving survival. He stated the reasons for absence of significant gain in survival out of IPT including most studies are not powered to look survival benefit and patients enrolled in the trials are often not those with advanced stage of disease and are under active surveillance and follow-up. Dr Haileyesus Getahun (Getahun_San Francisco CROI 2010) of WHO presented the outcome of a primary patient meta-analysis that was done to develop a rule to screen people living with HIV to put them on IPT and further investigations for TB or other diseases. He also shared the upcoming draft WHO recommendations on IPT and intensified TB screening among people living with HIV. Dr Alison Grant (Grant_San Francisco CROI 2010) of London School presented on the role of IPT in settings with high rates of drug resistance TB. She presented summary of the evidence and stated that IPT does not promote drug resistance TB and actually protection from IPT no is no worse with a background of INH resistance. However, she stated that there is scanty information that IPT may be less ineffective in individuals with latent INH resistant TB. There is no evidence about threshold prevalence of INH resistance at which IPT risks exceed benefits. Similarly there is no data on what to do for contacts with MDR TB cases and the available international guidelines are not consistent to each other. She suggested placebo controlled trials for MDR contacts using drugs like high dose INH, fluoroquinolones or new agents (e.g. TMC 207). From Mekong to Bali: the scale up of collaborative TB/HIV activities in Asia Pacific Region. 8-9 August, 2009, Bali, Indonesia.Catalyzing the implementation of collaborative HIV/TB activities in the Asia and Pacific regions is a key priority. This region has more than half of the global burden of TB and 12% of the global burden of HIV. To this end the meeting "From Mekong to Bali: scale up of HIV/TB collaborative activities in Asia Pacific" was organized by the World Health Organization (WHO) in collaboration with the HIV/TB Working Group of the Stop TB Partnership. 127 people from 18 countries participated in the meeting with representation from all high TB and HIV burden countries. Participants shared experiences and best practices to inform plans to accelerate the implementation of nation-wide scale up of collaborative HIV/TB activities. The meeting followed on from the first regional HIV/TB meeting held in the Mekong sub region in Ho Chi Minh City, Vietnam in October 2004. National TB and HIV program managers were joined by a broad range of AIDS and TB stakeholders active in the Asia and Pacific regions, members of the HIV/TB Working Group and representatives of bilateral and multilateral organizations, NGOS, and faith based organizations. The presentations and posters from the meeting are available below. The final meeting report will be available in due course. GeneralICAAP Plenary Session 1
TB/HIV at IAS 2009: Catalysing HIVT/TB Research: innovation, funding and networkingThe World Health Organization and the TB/HIV Working Group of the Stop TB Partnership in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), International AIDS Society, Treatment Action Group and the Desmond Tutu HIV Centre of University of Cape Town organized a highly visible meeting in conjunction with the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa on July 18-19, 2009. The meeting was attended by about 250 HIV researchers, activists and representatives from funding agencies. The meeting focused on critical TB/HIV issues in the areas of TB prevention, diagnosis and treatment, childhood TB and drug resistant TB. New and previously unreported data was shared, discussed and research priorities were defined. The research priority discussions during the meeting also informed the ongoing revision of the TB/HIV research priorities agenda. The outcome and key findings of the meeting were communicated to IAS conference delegates through a satellite symposium on July 21, 2009. Report of the meeting will be available soon. July 21, 2009Preventing TB in People Living with HIV: research priorities and way forward by Peter Godfrey-Faussett, UK TB in HIV-infected Children: addressing the research neglect by Soumya Swaminathan, India Drug resistance TB in People Living with HIV: research questions and priorities by Haileyesus Getahun, Switzerland Clinical challenges of diagnosing and treating TB in People Living with HIV: what next for research? By Prudence Ive, South Africa July 19, 2009Key note presentation Challenges on TB-HIV Research by Françoise Barré-Sinoussi, France Watch Dr. Barré-Sinoussi's plenary presentation  Research activism from HIV to TB by Mark Harrington, USA Session III: Childhood TB TB diagnosis in Children: experience with HIV-infected children by Anneke Hesseling, South Africa ARV TB drug experience in children: when and what to start? By Philippa Musoke, Uganda Mother to child transmission of TB: what do we know? By Amita Gupta, India Developing safer TB vaccines for children with HIV by Jerald Sadoff, USA Session IV: Drug resistance TB and HIV MDR, XDR TB and HIV: global data, approaches and operational research issues by Paul Nunn, Switzerland MDR and XDR TB in people living with HIV: what do we know and what we still need to know by Neel Gandhi, USA Drug resistance TB and new diagnostics for people living with HIV: emerging data from FIND by Giorgio Roscigno, Switzerland Molecular epidemiology: role for transmission of MDR/XDR by Paul van Helden, South Africa Read the presentations made at the meetingKey note presentations HIV/TB overview and rationale of meeting by Diane Havlir, USA Research on TB and HIV/AIDS: Progress and Challenges by Anthony Fauci, USA Watch Dr. Fauci's plenary presentation Session I: Diagnosis and Treatment Strategies for co-treatment: first and second line ART and TB treatment by Gary Maartens, South Africa Role of TB in early mortality of people living with HIV by Mina Hosseinipour, Malawi Sub-clinical TB among people living with HIV: what does the evidence say? By Haileyesus Getahun, Switzerland The latest developments in diagnosis and management of TB IRIS: what are the gaps? By Graeme Meintjes, South Africa Session II: TB Prevention Isoniazid preventive therapy: outcome of massive scale-up among miners in South Africa by Gavin Churchyard, South Africa TB infection control among people living with HIV: what do we know? By rod Escombe, UK Impact of ART on TB Prevention by Robin Wood, South Africa TB diagnosis in the community: approaches and outcomes by Helen Ayles, Zambia TB/HIV at CROI 2009The Stop TB Department of WHO in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) organized a meeting affiliated with the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) in Montreal, Canada. This is the third in a series of meetings organized since 2007. The meetings have successfully raised the profile of HIV/TB among HIV researchers in particular by sharing data from ongoing studies, identifying research gaps and stimulating further HIV/TB research. The main objective of the meeting at CROI 2009 was to promote high level scientific interchange of ideas and research priorities to have a better understanding of the magnitude and burden of TB (including drug resistant strains) especially in HIV prevalent settings. List of participantsRead the presentations made at the meeting |